|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2B
|
|
pubmed:dateCreated |
2006-4-19
|
|
pubmed:abstractText |
Although 5-Fluorouracil (5-FU) is widely used in chemotherapeutic treatment for gallbladder cancer, there is little evidence of its effectiveness. Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) are the major determinants of individual sensitivity to 5-FU, and the impact of TS and DPD expression on prognosis and 5-FU efficacy has been studied in gastrointestinal carcinomas.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1391-6
|
|
pubmed:meshHeading |
pubmed-meshheading:16619549-Aged,
pubmed-meshheading:16619549-Colonic Neoplasms,
pubmed-meshheading:16619549-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:16619549-Female,
pubmed-meshheading:16619549-Gallbladder Neoplasms,
pubmed-meshheading:16619549-Humans,
pubmed-meshheading:16619549-Immunohistochemistry,
pubmed-meshheading:16619549-Male,
pubmed-meshheading:16619549-Middle Aged,
pubmed-meshheading:16619549-Neoplasm Staging,
pubmed-meshheading:16619549-Prognosis,
pubmed-meshheading:16619549-Stomach Neoplasms,
pubmed-meshheading:16619549-Survival Rate,
pubmed-meshheading:16619549-Thymidylate Synthase
|
|
pubmed:articleTitle |
Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer.
|
|
pubmed:affiliation |
Department of Gastroenterological Surgery, Kobe University Graduate School of Medical Sciences, Kobe, Japan. ajiki@med.kobe-u.ac.jp
|
|
pubmed:publicationType |
Journal Article
|
